Product Liability

GLP-1 Receptor Agonists (Ozempic, Wegovy) Gastroparesis Litigation

GLP-1 Receptor Agonists (Ozempic, Wegovy) Gastroparesis Litigation — Product Liability class action lawsuit

Case Overview

This emerging multidistrict litigation (MDL) involves claims from users of GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Mounjaro, who allege they developed a severe medical condition known as gastroparesis, or "stomach paralysis." These drugs, wildly popular for diabetes management and weight loss, work by slowing down digestion, which helps control blood sugar and creates a feeling of fullness.

However, plaintiffs in the lawsuit claim that for some individuals, this effect is far more extreme and persistent, leading to a chronic condition where the stomach cannot empty itself properly. Symptoms include severe nausea, vomiting, abdominal pain, and malnutrition. The lawsuits allege that the drug manufacturers, Novo Nordisk and Eli Lilly, failed to adequately warn patients and the medical community about the risk of developing severe or long-lasting gastroparesis.

Frequently Asked Questions

Can I sue Novo Nordisk or Eli Lilly for gastroparesis caused by Ozempic or Wegovy?

Yes, if you developed gastroparesis after using Ozempic, Wegovy, or other GLP-1 receptor agonists, you may have grounds for a product liability lawsuit against the manufacturers. You can join the class action litigation if you meet the eligibility requirements, which typically include having a gastroparesis diagnosis following use of these medications.

How do I get money from a GLP-1 gastroparesis settlement?

If you're a class member and a settlement is reached, you can file a claim with the settlement administrator. You'll typically need to submit proof of your Ozempic or Wegovy use and gastroparesis diagnosis. Once approved, you'll receive your settlement award from the fund established by the defendants.

What symptoms of gastroparesis qualify for the GLP-1 drug lawsuit?

Gastroparesis symptoms that may qualify include severe stomach paralysis, nausea, vomiting, bloating, and difficulty digesting food after taking Ozempic, Wegovy, or similar GLP-1 drugs. Medical records documenting your diagnosis and its timing in relation to medication use are important for your claim.

Related Cases

Social Media Addiction & Youth Mental Health School District MDL — Product Liability class action lawsuit

Social Media Addiction & Youth Mental Health School District MDL

Current
Product Liability
Hundreds of school districts and personal injury plaintiffs allege that Meta, Snap, TikTok, and YouTube deliberately designed their platforms to be addictive to children and teenagers, causing a nationwide youth mental health crisis resulting in anxiety, depression, self-harm, eating disorders, and suicide.
Ozempic / Mounjaro GI Injury (Gastroparesis & Bowel Obstruction) Products Liability MDL — Product Liability class action lawsuit

Ozempic / Mounjaro GI Injury (Gastroparesis & Bowel Obstruction) Products Liability MDL

Current
Product Liability
Patients who used GLP-1 receptor agonist drugs Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight loss or diabetes management allege they suffered severe gastrointestinal injuries — including gastroparesis (stomach paralysis), bowel obstruction, and intestinal ileus — that were not adequately disclosed in the drugs' warnings.
Victoza (Liraglutide) Lawsuit: Vision Loss (NAION) Claims — Product Liability class action lawsuit

Victoza (Liraglutide) Lawsuit: Vision Loss (NAION) Claims

Current
Product Liability
Victoza (liraglutide) lawsuits claim that Novo Nordisk failed to warn patients about the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden vision loss. Users of the GLP-1 diabetes drug allege that the manufacturer did not adequately disclose the potential eye damage risks.